Experimental drug for rare blood disorder tested for long-term safety
Disease control
Terminated
This study tested the long-term safety of a drug called SAR445088 in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. Only 9 participants were enrolled, and the study was terminated early. The goal was to see if the drug is sa…
Phase: PHASE1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 16:38 UTC